Navigation Links
Europe's Columbus laboratory leaves Earth
Date:2/7/2008

s to control their experiments and receive real-time data on their results.

European building blocks for the station

Although Columbus is ESAs major contribution to the ISS, it is neither the first, nor will it be the last to be launched. ESA has already provided a Data Management System for the Russian segment (DMS-R) and several research equipment racks already in operation, such as the Microgravity Science Glovebox or the Minus Eighty degrees Lab for ISS freezer. Under a barter agreement with NASA, ESA also provided the Harmony (Node 2) connecting module, delivered by the previous shuttle flight, in October. In early March an Ariane 5 launcher will also lift the 'Jules Verne' unmanned freighter, the first of a series of Automated Transfer Vehicles which will serve both for servicing and re-boost of the station. Other European contributions scheduled in the future include the European Robotic Arm, the Node 3 module and the Cupola observation post.

The launch of Columbus marks the onset of a new era. We have long waited for this moment in European human spaceflight and space-related sciences, said Daniel Sacotte, ESAs Director for Human Spaceflight, Microgravity and Exploration Programmes. The first decision to study Columbus was taken back in 1985. At that time it was planned as a contribution to NASAs Space Station Freedom project. As the world changed, the station was redesigned and became a truly international programme. We were able to initiate full-scale development of Columbus some twelve years ago. Today Columbus is a reality, a laboratory in space far more capable than what we proposed in 1985, and even than what we planned in 1995, as we benefited from the delays in ISS assembly to improve our design and our equipment. Columbus is now a world-class space laboratory, ready for 10 years of exciting science experiments.

When the hatch is opened and the astronauts enter Columbus to switch on and commission its sci
'/>"/>

Contact: media.relations@esa.int
33-153-697-299
European Space Agency
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Knights of Columbus to Distribute Wheelchairs to Veterans in Need
2. Columbus Carried Syphilis From New World to Europe, Study Suggests
3. Laboratory at UI plays major role in diagnosing cancer
4. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
5. Epilepsy-induced brain cell damage prevented in the laboratory
6. Story tips from the Department of Energys Oak Ridge National Laboratory, Nov. 2007
7. ThalesNano Inc. and the Christian Doppler Laboratory for Microwave Chemistry in Graz, Austria Collaborate on Flow Chemistry Technologies
8. MCG selected as RNA laboratory for worldwide diabetes study
9. Inverness Medical Innovations to Acquire Redwood Toxicology Laboratory
10. Novel anticancer strategy moves from laboratory to clinic
11. Tethys Bioscience Hits Key Milestones With Series C Funding, Opening of CLIA Laboratory

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , Dr. Redlener Applauds Historic Effort b...et Programs Are Lost in Final Health Care Reform ... The New England Journal of Medicine today pub...th care reform, co-authored by Irwin Redlener, M.D... National Center for Disaster Preparedness and Pro...
(Date:12/4/2009)...with knowledge of risks, many hesitate to take bre... Dec. 4 (HealthDay News) -- Worries about side eff...ican women at high risk for breast cancer are will...ase, a new study finds. , In an effort to infor... researchers at the University of Michigan Compreh...
(Date:12/4/2009)... , BOULDER, Colo., Dec. 4 ..., ON LOVE ,, Kathryn Budig, a prominent yoga te...e to healing--with a viewing of Twilight,s New Moo...nal.com: ,, http://www.elephantjournal.com/200...ournal.com: TASHI KING AND BREAST CANCER ,, el...
(Date:12/4/2009)... , JEFFERSON CITY, Mo., Dec. 4 /PRNewswire/ ...ctor Paul Crosetti, State Fire Marshal Randy Cole,...en,s fire safety program sponsored by Farmers call... safety day at the Missouri Capitol December 9. .../20080605/LATH062 ) ,, "The call for fire safet...
(Date:12/4/2009)...le who have had an ischemic stroke are at higher l... of medication can reduce that risk. One of the si...s, otherwise known as blood thinners, of which the...tudy to determine whether the use of antithromboti...r a seven-year period found that in each of the ye...
Breaking Medicine News(10 mins):Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Missouri Safety Day at the Capitol 2Health News:Are stroke survivors taking their medicine? 2
..., Dec. 3 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP...igational new,drug (IND) application to the U.S. F...und is an internally developed, orally-bioavailabl...r,patients in early 2008., "This IND submission i...
... N.Y., Dec. 3 Big A Drug Stores, Inc. has,selecte...al estate,solutions, to exclusively manage the dis...California. Big A Drug Stores, Inc. is a chain of ...gs,","Drug Fair," and "Drug Barn" (2 stores)., "W...
...APOLIS Although more and more drug advertisements...oximately $21 billion dollars that pharmaceutical ...is targeted to physicians, doctors in training (re...c. published in the December issue of the journal ...
...and PITTSBURGH, Dec. 2 Forest,Laboratories, Inc. ...ed that,Mylan has received an approvable letter fr...response to its New Drug Application (NDA) for,neb...icated that a recent inspection of,a backup manufa...
... communication with doctors and respect for role o...Y, Dec. 2 (HealthDay News) -- The death of a child...dparents, siblings, friends, even the child,s doct...ymptoms and stress of life-threatening illness -- ...
...ESTER, Ill. Hospital staff nurses who work extend...at work, or obtain less sleep are more likely to e... study published in the December 1 issue of the jo...ed from 895 full-time hospital staff nurses, who c...
Other Medicine News:Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 2Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 3Health News:Big A Drug Stores, Inc. Retains DJM Realty to Dispose of All Stores Operating Under the Names of Drug Emporium, Big A, Camelot, Drug Fair and Drug Barn 2Health News:Do medical schools affect the way future doctors interact with drug companies? 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 3Health News:Breaking Down Barriers to End-of-Life Care for Children 2Health News:Breaking Down Barriers to End-of-Life Care for Children 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 4
(Date:12/4/2009)..., , BETHESDA, Md., Dec. 4 Dr...lts for prostate-specific antigen (PSA) recurrence...nts of biochemical recurrence rate in a Phase III ... for injection) or monthly leuprolide in prostate .... Prostate cancer patients who received FIRMAGON ...
(Date:12/3/2009)..., , NEW YORK, Dec. 3 Guid...rm, today announced the launch of their Sleep Apne...t monitors and projects trends and market share in...p Apnea Tracker captures actual patient usage for ...nited States from 15 different equipment providers...
(Date:12/3/2009)..., , SUNNYVALE, Calif., Dec. 3 /PRNewswire-..., a biopharmaceutical company focused on developin...ugs for the treatment of immune mediated diseases ...bcast and conference call on, Tuesday, December 8,...e and 8:00am Pacific Time) to discuss clinical dat...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 1Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 3ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 1ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 1CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 3
...AS, April 4, 2008 Data from five studies sponsore...d at the National Kidney,Foundation (NKF) 2008 Spr...e utilization studies involve PROCRIT(R) (Epoetin ...g utilization patterns and,costs of PROCRIT (EPO) ...s,related to chronic kidney disease (CKD) patients...
...iously-Stated Guidance Remains Unchanged, PRINCET...EDX ) today issued the following statement in resp... discontinuing its Phase 3 clinical,trial of front...LA-4,antibody (tremelimumab) compared to chemother...ey M. Nichol, M.B.Ch.B., Senior Vice President, Pr...
Other Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
HOME MULTI-DRUG TEST
SEDIPLAST ESR SYSTEM (with diluent)
SEDIPLAST ESR SYSTEM (without diluent)
Hemaprompt FG Gastric and Fecal Occult Blood Test
Medicine Products: